Abstract
Carbon monoxide (CO) has long been considered a purely toxic by-product of incomplete combustion processes. Acute exposure to high concentrations of CO is one of the leading causes of fatal poisoning in industrial countries. However, after two decades of intensive research, there is ample evidence that CO endogenously produced by heme oxygenase enzymes has essential physiological functions and is of vital importance for cellular hemostasis. Furthermore, exogenously applied CO in low concentrations mediates potent cytoprotective effects. An overwhelming number of different in vitro and in vivo models demonstrated the protective action of CO application, e.g., in ischemia/reperfusion, transplantation, oxidative stress, inflammation, and others. Protection by this gaseous molecule could be illustrated for most organs, most species, and for different routes of administration. Now being on the verge of entering clinical trials, the question emerges whether the administration of low-dose CO would be safe for patients when used as a potential therapeutic. Therefore, this review summarizes in particular toxicological data obtained from low-dose CO exposure and discusses its impact on a possible clinical application.
Keywords: Carbon monoxide, toxicity, heme oxygenase, HO-1, organ protection, stress response
Current Pharmaceutical Biotechnology
Title:Carbon Monoxide - Toxicity of Low-Dose Application
Volume: 13 Issue: 6
Author(s): Rene Schmidt, Helen Ryan and Alexander Hoetzel
Affiliation:
Keywords: Carbon monoxide, toxicity, heme oxygenase, HO-1, organ protection, stress response
Abstract: Carbon monoxide (CO) has long been considered a purely toxic by-product of incomplete combustion processes. Acute exposure to high concentrations of CO is one of the leading causes of fatal poisoning in industrial countries. However, after two decades of intensive research, there is ample evidence that CO endogenously produced by heme oxygenase enzymes has essential physiological functions and is of vital importance for cellular hemostasis. Furthermore, exogenously applied CO in low concentrations mediates potent cytoprotective effects. An overwhelming number of different in vitro and in vivo models demonstrated the protective action of CO application, e.g., in ischemia/reperfusion, transplantation, oxidative stress, inflammation, and others. Protection by this gaseous molecule could be illustrated for most organs, most species, and for different routes of administration. Now being on the verge of entering clinical trials, the question emerges whether the administration of low-dose CO would be safe for patients when used as a potential therapeutic. Therefore, this review summarizes in particular toxicological data obtained from low-dose CO exposure and discusses its impact on a possible clinical application.
Export Options
About this article
Cite this article as:
Schmidt Rene, Ryan Helen and Hoetzel Alexander, Carbon Monoxide - Toxicity of Low-Dose Application, Current Pharmaceutical Biotechnology 2012; 13 (6) . https://dx.doi.org/10.2174/138920112800399103
DOI https://dx.doi.org/10.2174/138920112800399103 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Parasite Polyamines as Pharmaceutical Targets
Current Pharmaceutical Design Pulmonary Complications After Congenital Heart Surgery
Current Respiratory Medicine Reviews Myocardial Inflammation in Autoimmune Diseases: Investigation by Cardiovascular Magnetic Resonance and Endomyocardial Biopsy
Inflammation & Allergy - Drug Targets (Discontinued) Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Novel Strategies for the Detection of Systolic and Diastolic Heart Failure
Current Cardiology Reviews Biomarkers in Lone Atrial Fibrillation-An Additional ‘Fine Tuning’ of Risk?
Current Pharmaceutical Design Respiratory Tract Manifestations of Rheumatic Diseases in Children
Current Respiratory Medicine Reviews Ibubrofen in the Treatment of Patent Ductus Arteriosus in Preterm Infants: What We Know, What We Still Do Not Know
Current Pharmaceutical Design Clinical Characteristics and Treatment of Cardiomyopathies in Children
Current Cardiology Reviews Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Neonatal Hypertension: An Underdiagnosed Condition, A Review Article
Current Hypertension Reviews A Review of Maternal and Fetal Growth Factors in Diabetic Pregnancy
Current Diabetes Reviews Perinatal Heart Programming: Long-term Consequences
Current Medicinal Chemistry Protective Effects of Curcumin against Iron-induced Toxicity
Current Pharmaceutical Biotechnology Nursing Assessment, Education, and Care of Extremely Premature Neonates with Patent Ductus Arteriosus
Current Pediatric Reviews Pompe Disease: From New Views on Pathophysiology to Innovative Therapeutic Strategies
Current Pharmaceutical Biotechnology Large Unrepaired Aortopulmonary Window Presenting in Adulthood
Current Cardiology Reviews Tuberculous Pericarditis
Current Cardiology Reviews Value of Carnitine Therapy in Kidney Dialysis Patients and Effects on Cardiac Function from Human and Animal Studies
Current Drug Targets Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews